The first report of LCNEC carrying an EGFR activating mutation and of gefitinib activity in LCNEC patients was published in July 2010; a 66-year-old woman who had never smoked was diagnosed with metastatic LCNEC. Here, EGFR is linked to large cell neuroendocrine carcinoma.